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Aims: Blastocystis is an anaerobic, enteric, protistan parasite
with zoonotic potential. Its clinical relevance has been de-
bated extensively, as some studies support a pathogenic role
for the parasite while others show no correlation between in-
fection and disease. Humans can be infected by a variety of
distinct genotypes (subtypes). We hypothesize that subtypes vary
in pathogenic potential and we aimed to investigate if such
differences can be observed using in vitro cytopathic assays.
Methods & Results: Investigations were carried on Blastocystis
subtypes 4 and 7, which are zoonotic genotypes found in ro-
dent and avian hosts respectively. Cysteine protease activity was
determined by azocasein assay. The results revealed inter- and
intra-subtype variations in protease activity, with subtype 7 iso-
lates harboring higher cysteine protease levels. Apoptosis assays
for phosphatidylserine (PS) externalization and nuclear blebbing
revealed that subtype 7 induced more cell death in host cells
than subtype 4. Similarly, transwell assays for barrier function
showed that subtype 7 induced greater barrier disruption than
subtype 4. A stress ﬁber model developed in Caco-2 colonic ep-
ithelial cells, revealed that subtype 7 induced reorganization of
stress ﬁbers with a possible link to barrier function compromise.
Conclusions: From this study, clear cytopathic differences exist
between Blastocystis subtypes, which suggest that variations in
pathogenic potential exists among Blastocystis genotypes from
different animal hosts.
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Several epidemic outbreaks of Enterovirus 71 (EV71) infection oc-
curred during the past one decade in southern Taiwan. EV71 has
the potential to cause a large outbreak worldwide such as that
in Taiwan in 1998. The main clinical presentations are herpang-
ina, hand-foot-and-mouth disease (HFMD), and central nervous
system (CNS) complications. Brain stem encephalitis (BE) is the
cardinal feature of EV71 CNS complications during the outbreak.
The predominant neurological presentations are myoclonus jerk,
vomiting, and ataxia. BE that progressed abruptly to neurogenic
shock and pulmonary edema (PE) was indicative of poor prognosis
and high mortality. EV71 BE was categorized into uncomplicated
BE, autonomic nervous system (ANS) dysregulation, and PE by
disease severity. The PE that occurs in children with EV71 BE is
caused by abnormal cytokines activation that produces severe
CNS and systemic inﬂammatory responses. Currently, there is
no speciﬁc antiviral agent to treat or vaccine to prevent EV71
diseases. Intravenous immunoglobulin (IVIG) has been found to
have broad therapeutic applications for the treatment of many
infectious diseases. We found a decrease in the plasma con-
centration of various cytokines following administration of IVIG.
Patients with ANS dsyregulation is the critical timing to received
IVIG infusion. It is possible that a more favorable survival might
have been obtained by earlier therapy and larger doses of IVIG.
Milrinone, cyclic nucleotide phosphodiesterase inhibitor subtype
III, increases cardiac output, and reduces systemic vascular resis-
tance and pulmonary capillary wedge pressure without excessive
increases in myocardial oxygen consumption. EV71-associated
PE patients treat with milrinone is associated with signiﬁcantly
decreased mortality by attenuated sympathetic activity and
cytokine production. Controlled clinical trials are ongoing to
conﬁrm these observations. A better understanding of the clin-
ical features and management of EV71 BE may shed light on
improving the outcome of severe and complicated EV71 BE.
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The main role of antiviral drug therapy for chronic hepatitis B
(CHB) infection is to suppress the hepatitis B virus (HBV) from
active replication, thereby preventing hepatitis and the com-
plications. Doctors and patients alike wished for achieving HBV
eradication early. This will lower the risk of liver complications
and restore health and quality of life of the CHB patients. From
the healthcare provider point of view, the transmission of HBV
infection can be minimized and the health cost substantially
reduced. Eradication of HBV rarely occurs spontaneously; around
0.5 to 2% among CHB individuals lost HBsAg annually. Newer an-
tiviral drugs have higher efﬁcacy and safety. HBsAg loss over and
above the estimated spontaneous incidence has been reported
after and during therapy. The role of current available antiviral
drugs in the full spectrum of CHB disease can be summarized as
follows.
There are two main categories of antiviral therapy for HBV infec-
tion: (1) interferon-based injections, and (2) oral nucleos(t)ide
analogues. Any HBV disease types with viraemia will beneﬁt from
antiviral therapy that is efﬁcacious, safe and affordable. Most
international and national HBV treatment guidelines focused on
individuals with HBV DNA level over 5 log10 copies/ml (i.e. around
4 log10 IU/L); especially if HBeAg negative; associated with raised
serum ALT; and have evidence of signiﬁcant liver ﬁbrosis. Antivi-
ral therapy is particularly important among males, over middle
age, has family history of cirrhosis and hepatocellular carcinoma
(HCC). The aim is to halt the existing liver damage, hopefully
reverse ﬁbrosis, even cirrhosis, and eliminate the conditions
that favour HCC development. Clinical experience and data do
support such strategy.
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Interferon-based anti-viral drugs have dual actions of viral sup-
pression and immune modulation; thereby have a higher chance
of eradicating HBV and the infected hepatocytes. Pegylated in-
terferon alfa-2a therapy for one year resulted in incremental
HBsAg loss up to 9% and 11% by year 3 and year 4 respectively
after completion of therapy. Higher baseline ALT level, female
patients, HBV genotype A have been reported to favour response.
The viral kinetics during therapy, the proﬁle of decline in serum
HBV DNA, quantitative HBeAg and HBsAg levels, are useful in
identifying the patients likely to achieve sustained virologic re-
sponse, which is relatively low at 30-40%. The deﬁned duration of
therapy make pegylated interferon therapy a choice for treating
younger patients planning family in the future. These patients
need careful counselling and should be warned about immediate
and longer term known side-effects. They should be followed and
monitored regularly at 4 to 8 weekly intervals. Long term follow-
up data showed a signiﬁcant reduction in serious complications
of CHB including reduced incident of hepatocellular carcinoma
among those responded to standard interferon therapy. Similar,
if not better, results are anticipated after therapy with peylated
interferon.
Oral nuceos(t)ide analogues (NAs) act directly and purely by
suppressing the HBV DNA polymerase, though there may be some
secondary stimulus effect on the host immune system when viral
load is suppressed rapidly. NAs have the distinct advantage of
low primary non-responder rate. Lamivudine and adefovir have
been available for many years. Clinical experience over the years
showed high rate of emergence of resistant mutants and moder-
ate antiviral effect. Patients on these NAs require more frequent
monitor and add-on therapy should resistance developed. Tel-
bivudine, by comparison, is more potent and has lower resistant
proﬁle. The choice is easier when entecavir and tenofovir be-
come available in the market. The consistent and rapid viral
suppression, coupled with a much, much lower incident of drug
resistant make long term therapy possible. Side-effects are few.
The efﬁcacy is not age, gender, ALT, and HBV genotype dependent
and can be used in patients with cirrhosis and decompensated
disease.
Pivotal clinical trials usually recruit patients of certain age group
and speciﬁc disease characteristics. The role and safety of the
newer NAs in the children and young adults with CHB, patients
in immune tolerant phase, and in pregnant women, are still
not clear. The role of NA as a prophylactic therapy to prevent
relapse or exacerbation of CHB during chemotherapy or steroid
treatment has been demonstrated. Another milestone role of
NA is the suppression of HBV in liver and other organ/tissue
transplantations. The success of transplantation for CHB patients
cannot be realized without potent suppression of HBV to stamp
out HBV recurrence in the immune compromised state.
Current available therapy has created a signiﬁcant impact in HBV
infection and has improved the prognosis of CHB patients. Much
more advances are needed to control this disease, to inhibit more
profoundly, to eradicate more rapidly. We are at a turning point
and should witness a downward trend in mortality and morbidity
of cirrhosis and HCC, the real goal of HBV therapy.
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China is a highly endemic area for hepatitis B virus (HBV) in-
fection with the biggest HbsAg carrier population in the world.
The management of chronic hepatitis B (CHB) has improved
dramatically over the last decade with the development of new
antiviral drugs. In addition to the standard interferon (IFN)-
alpha therapy, 4 nucleotide/nucleoside analogues (lamivudine,
adefovir dipivoxil, entecavir and telbivudine) and 2 pegylated
interferon (pegasys and pegintron) have been approved for the
treatment of chronic hepatitis B. Long-term therapy with nucle-
oside/nucleotide analogues, both in HBeAg+ and HBeAg- CHB,
has most favourable effects on patient outcome, provided that
virological and biochemical remission is maintained without de-
velopment of viral resistance. However, drug resistance become
increasingly challenging to clinical management of patients with
CHB. Here I would like to focus my presentation on 2 recent
studies related with HBV resistance in China.
The ﬁrst study is an open-label, randomized, controlled study to
compare the efﬁcacy and safety of peginterferon alfa-2a versus
adefovir dipivoxil (ADV) in treating lamivudine resistant HBeAg
positive CHB. Up to 70% of patients treated with lamivudine
develop drug resistance after 5 years. Rescue therapies with
oral antivirals are limited due to the cross-resistance proﬁles of
nucleos(t)ide analogs. A ﬁnite course of peginterferon alfa-2a
can offer the possibility of achieving sustained post-treatment
response in these difﬁcult-to-treat patients. In order to deter-
mine if on-treatment quantiﬁcation of HBsAg can help identify
the patients with lamivudine-resistant HBV most likely to achieve
sustained post-treatment response to peginterferon alfa-2a,
quantitative HBsAg levels were measured retrospectively at base-
line and at week 24 and 48 using the Architect QT assay (Abbott
Diagnostics) in available sera of 155 patients who received pegin-
terferon alfa-2a 180 μg qw for 48 weeks or 80 patients with ade-
fovir dipivoxil (ADV) 10mg daily for 72 weeks. All patients were
HBeAg-positive with documented resistance to lamivudine (YMDD
mutation). All patients continued LAM treatment 100mg daily
for the ﬁrst 12 weeks. The primary efﬁcacy endpoint was HBeAg
seroconversion at Week 72 (6 months post-treatment in pegin-
terferon alfa-2a arm or at the end of treatment in adefovir arm).
HBeAg seroconversion at Week 72 was signiﬁcantly higher in the
peginterferon alfa-2a arm (11.6% vs 3.8%, p=0.045). Three of
the 18 patients treated with peginterferon alfa-2a who achieved
HBeAg seroconversion also achieved HBsAg seroconversion. No
ADV-treated patient cleared HBsAg. HBsAg decline from base-
line was more pronounced in the peginterferon alfa-2a-treated
patients. At week 24, 31% of the peginterferon alfa-2a-treated
patients with available data had HBsAg levels <1500 IU/ml,
compared with 14% of those treated with ADV. The rate of HBeAg
seroconversion 6 months post-treatment was twice as high in
peginterferon alfa-2a-treated patients with HBsAg <1500 IU/ml
at W24. There was no association between HBsAg level at week
24 and response to ADV.
Our data show that peginterferon alfa-2a represents a vi-
able treatment strategy for difﬁcult-to-treat patients who bear
lamivudine-resistant YMDD mutations and was superior to ADV
in achieving HBeAg seroconversion. Quantiﬁcation of HBsAg level
at week 24 may help identify those most likely to beneﬁt from
peginterferon alfa-2a.
The second study is about adefovir dipivoxil (ADV) resistance at
5 years in Chinese HBeAg+ve chronic hepatitis B. Long term ADV
provides clinical and histological improvement in CHB, but as
with all oral therapies may lead to emergence of ADV resistance-
associated mutations. Long term ADV resistance data are best
documented in a HBeAg negative population. At 5 years the
cumulative probability of resistant mutation with virological re-
sistance was 29%. We report ADV resistance data from a cohort
of Chinese HBeAg positive subjects treated for 5 years.
Four hundred and eighty HBeAg positive CHB subjects were ran-
domized in an initial 52 weeks controlled ADV study (with a
12 weeks placebo period in two thirds of patients) and then
offered open label ADV treatment for a further 208 weeks. Four
hundred and eighty subjects were enrolled in the ﬁrst year study,
